

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ENTERPRISE DEVELOPMENT HOLDINGS LIMITED

企展控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1808)

FURTHER ANNOUNCEMENT

IN RELATION TO THE DISCLOSEABLE TRANSACTION

LIMITED PARTNERSHIP AGREEMENT

Reference is made to the announcement of Enterprise Development Holdings Limited (the “**Company**”) dated 17 May 2025 in relation to, among others, the execution of the Hainan Yayi Partnership Agreement (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement bear the same meanings as those defined in the Announcement.

The Board would like to provide further information in relation to the Hainan Yayi Partnership. Hainan Yayi Partnership is a limited partnership with its business scope including, but not limited to, investment activities with own funds and asset management services for investment with own funds, particularly to invest in corporations with activities in medical research and experimental development, cell technology research and development and application, medical research and experimental development (except human stem cells, gene diagnosis and treatment technology development and application), natural science research and experimental development, biomass energy technology services, engineering and technical research and experimental development, technical services, technology development, technology consulting, technology exchange, technology transfer, technology promotion. Hainan Yayi Partnership is looking for investment in biomedicine related corporations.

The Company through its indirect wholly-owned subsidiary acts as the sole managing partner of Qitong Fuyuan and has invested RMB120 million in Hainan Yayi Partnership.

Hainan Yayi Partnership has acquired 14.16% equity interest in 賽隆藥業集團股份有限公司 (the “**Target Company**”), a company with its shares listed on Shenzhen Stock Exchange (stock code: 002898), which focused on biomedical industries, at a consideration of RMB199 million.

The Board is pleased to announce that on 9 July 2025, the Target Company received the Securities Transfer Registration Confirmation issued by China Securities Depository and Clearing Corporation Limited, and the transfer registration procedures for Hainan Yayi Partnership's acquisition of 14.16% equity interest in the Target Company were completed on 8 July 2025.

By Order of the Board
Enterprise Development Holdings Limited
Yu Hui
Executive Director and Chief Executive Officer

Hong Kong, 10 July 2025

As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Yu Hui (chief executive officer) and Ms. Li Zhuoyang, and three independent non-executive Directors, namely Mr. Cai Jinliang, Mr. Chin Hon Siang and Mr. Chen Kwok Wang.